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PURPOSE. To compare spectral-domain optical coherence tomography (SD-OCT) standard
structural measures and a new three-dimensional (3D) volume optic nerve head (ONH)
change detection method for detecting change over time in severely advanced-glaucoma
(open-angle glaucoma [OAG]) patients.
METHODS. Thirty-five eyes of 35 patients with very advanced glaucoma (defined as a visual field
mean deviation < 21 dB) and 46 eyes of 30 healthy subjects to estimate aging changes were
included. Circumpapillary retinal fiber layer thickness (cpRNFL), minimum rim width (MRW),
and macular retinal ganglion cell–inner plexiform layer (GCIPL) thicknesses were measured
using the San Diego Automated Layer Segmentation Algorithm (SALSA). Progression was
defined as structural loss faster than 95th percentile of healthy eyes. Three-dimensional
volume ONH change was estimated using the Bayesian-kernel detection scheme (BKDS),
which does not require extensive retinal layer segmentation.
RESULTS. The number of progressing glaucoma eyes identified was highest for 3D volume
BKDS (13, 37%), followed by GCPIL (11, 31%), cpRNFL (4, 11%), and MRW (2, 6%). In
advanced-OAG eyes, only the mean rate of GCIPL change reached statistical significance,
0.18 lm/y (P ¼ 0.02); the mean rates of cpRNFL and MRW change were not statistically
different from zero. In healthy eyes, the mean rates of cpRNFL, MRW, and GCIPL change were
significantly different from zero. (all P < 0.001).
CONCLUSIONS. Ganglion cell–inner plexiform layer and 3D volume BKDS show promise for
identifying change in severely advanced glaucoma. These results suggest that structural
change can be detected in very advanced disease. Longer follow-up is needed to determine
whether changes identified are false positives or true progression.
Keywords: advanced glaucoma, structural change, 3D change detection, rate of change
Primary open-angle glaucoma (OAG) is often an asymptom-atic disease at its most treatable stages and can therefore be
quite advanced at the time of initial detection, particularly in
high-risk populations. An estimated 10% to 39% of patients
present with advanced glaucoma (OAG), and many are
asymptomatic at the time of diagnosis.1–3 Moreover, as the
population ages and life expectancy increases, a larger
proportion of patients will develop advanced disease. Ad-
vanced-OAG patients are, however, at the highest risk of
becoming functionally impaired due to the disease and are the
costliest to treat.4–6 Clinicians need to know whether the
patient is stable on the current therapy or whether the patient
is progressing and therapy needs to be intensified.
Unfortunately, there are currently no accepted standards for
which tests are most effective for detection of progressive
glaucoma in advanced OAG. Assessment of glaucoma progres-
sion in early stages of the disease is usually performed by
detecting change over time in structural and functional
measurements such as circumpapillary retinal nerve fiber layer
thickness (cpRNFL), optic nerve head (ONH) neuroretinal
minimum rim width (MRW), retinal ganglion cell–inner
plexiform layer (GCIPL) thickness, and visual field mean
deviation (VF MD).7–9 However, monitoring advanced OAG
using standard structural and functional testing is extremely
difficult for the treating clinician since both standard structural
and functional tests that usually guide treatment decisions are
of diminished value. This is because standard structural
measures have a limited dynamic range as they thin with
advanced OAG, and visual field (VF) test points are more
variable in advanced disease.10–16 Complicating matters further,
recent reimbursement criteria in the United States have limited
the use of imaging in advanced OAG17 because VF testing is
considered more diagnostic in advanced disease.
Despite advances in spectral-domain optical coherence
tomography (SD-OCT) imaging, few studies have evaluated
whether SD-OCT can detect structural change in advanced
disease. Evidence suggests that in advanced OAG, the
papillomacular bundle is more resistant to glaucomatous
damage and shows better agreement with VF progression than
cpRNFL and thus may be used to monitor glaucomatous change
in late stages of the disease.7,8
Recently, we proposed a new glaucoma change detection
method (Bayesian-kernel detection scheme [BKDS]) that
utilizes the whole three-dimensional (3D) SD-OCT ONH and
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does not require extensive retinal layer segmentation.18,19 In
early- to moderate-glaucoma eyes with progressing VF damage,
while maintaining high specificity the BKDS method had
higher sensitivity for detecting progression than cpRNFL.18,19
This method also has the advantage that it detects 3D change in
a region of interest, which can include deeper layers such as
the lamina cribrosa. Reports suggest that in eyes with advanced
glaucoma, the lamina cribrosa changes its shape by developing
a W-shaped configuration.20 Others have reported that the
lamina cribrosa is cupped and excavated beneath the scleral
canal rim in advanced-OAG eyes.21
The purpose of this study was to determine whether MRW,
cpRNFL, and GCIPL thinning can be detected in very advanced
OAG eyes and to compare the number of progressing OAG
eyes using these measurements with a new 3D ONH whole-
volume change detection method, BKDS.
METHODS
Subjects
Patients with primary OAG and healthy subjects included in
this study were recruited from the Diagnostic Innovations in
Glaucoma Study (DIGS) and African Descent and Glaucoma
Evaluation Study (ADAGES). The multicenter ADAGES includes
participants from the Hamilton Glaucoma Center at the
Department of Ophthalmology, University of California-San
Diego; the New York Eye and Ear Infirmary; and the
Department of Ophthalmology, University of Alabama at
Birmingham. The Diagnostic Innovations in Glaucoma Study
includes participants recruited at the University of California-
San Diego. All the methods adhered to the tenets of the
Declaration of Helsinki and to the Health Insurance Portability
and Accountability Act. The institutional review boards at the
University of California-San Diego, New York Eye and Ear
Infirmary, and University of Alabama at Birmingham approved
the methods. All participants of the study gave written
informed consent. The African Descent and Glaucoma
Evaluation Study and DIGS are registered as cohort clinical
trials (http://www.clinicaltrials.gov, identifiers NCT00221923
and NCT00221897, September 14, 2005).
Methodological details of DIGS and ADAGES have been
described previously.22 In brief, for glaucoma subjects,
inclusion criteria were 20/40 or better best-corrected visual
acuity at baseline, spherical refraction within 65.0 diopters
(D), cylinder correction within 63.0 D, open angles on
gonioscopy, and at least two consecutive and reliable standard
automated perimetry VF examinations with either a pattern
standard deviation (PSD) or a glaucoma hemifield test (GHT)
result outside the 99% normal limits. Exclusion criteria were
eyes with coexisting retinal disease and eyes with non-
glaucomatous optic neuropathy.
For healthy subjects, inclusion criteria were 20/40 or better
best-corrected visual acuity, spherical refraction within 65.0
D, cylinder correction within 63.0 D, IOP < 22 mm Hg with
no history of elevated IOP, and at least two reliable normal VFs,
defined as a PSD within 95% confidence limits and a GHT result
within normal limits.
All subjects underwent an annual comprehensive ophthal-
mologic examination including review of medical history, best-
corrected visual acuity, slit-lamp biomicroscopy, dilated fundu-
scopic examination, and stereoscopic optic disc photography.
Semiannual examination included intraocular pressure (IOP),
SD-OCT imaging (SD-OCT circular scan, SD-OCT ONH cube
scan, SD-OCT ONH radial scan, and SD-OCT macular cube
scan), and VF testing.
In this report, we included three groups of participants. The
first group was composed of 35 eyes of 35 advanced-glaucoma
patients (VF MD  21 dB) followed for an average of 3.5 6
0.9 years. All eyes were followed at approximately 6-month
intervals with VF and OCT testing and were required to have a
minimum of three VFs and three OCTs during follow-up for
inclusion in this study (number of tests ranged from three to
eight).
The stable glaucoma group of consisted of 50 eyes from 27
early-, moderate-, and advanced-glaucoma patients with five
serial OCT exams imaged every week for 5 weeks. We assume
that in this short follow-up period, glaucoma changes are not
likely to occur. These stable glaucoma eyes were used to train
the BKDS ONH volume change method to reduce the
likelihood that changes due to measurement variability would
be classified as progression due to glaucoma.
A third group of 46 eyes from 30 healthy subjects followed
for an average of 2.86 0.4 years was used to estimate the aging
effects. All eyes were followed at approximately 6-month
intervals with VF and OCT testing and had an average of six
tests acquired during follow-up (test range was 4–10). Healthy
participants were recruited from the general population
through advertisement, from referring practices, and from
the staff and employees from the Shiley Eye Institute,
University of California, San Diego.
Imaging
Each subject was required to have at least one good-quality
Spectralis SD-OCT (Heidelberg Engineering Inc., Heidelberg,
Germany) circular scan, SD-OCT ONH cube scan, SD-OCT
ONH radial scan, and SD-OCT macular cube scan acquired on
the same day. Spectralis OCT uses a dual-beam SD OCT, a
confocal laser-scanning ophthalmoscope with a wavelength of
870 nm, and an infrared reference image to obtain images of
ocular microstructures. The instrument has an acquisition rate
of 40,000 A-scans per second. Spectralis OCT incorporates a
real-time eye-tracking system that couples confocal laser-
scanning ophthalmoscope and SD OCT scanners to adjust for
eye movements and to ensure that the same location of the
retina is scanned over time. The image acquisition protocols
included (1) high-resolution RNFL circle scan, which consists
of 1536 A-scan points from a 3.45-mm circle centered on the
optic disc, (2) high-resolution cube scan centered on the optic
disc (73 B-scans with 768 A-scans each), (3) enhanced depth
imaging (EDI) scan centered on the optic disc (48 B-scans with
1024 A-scans each), and (4) high-resolution cubic scan
centered on the fovea (73 B-scans with 768 A-scans each).
Quality assessment of OCT scans was evaluated by Imaging
Data Evaluation and Assessment (IDEA) Center experienced
examiners masked to the subject’s results of the other tests.
San Diego Automated Layer Segmentation
Algorithm (SALSA)
Raw 3D SD-OCT images were exported to a numerical
computing language (MATLAB; MathWorks, Natick, MA,
USA). The San Diego Automated Layer Segmentation Algorithm
(SALSA) was used to automatically segment (1) the Bruch’s
membrane opening (BMO) and the internal limiting membrane
(ILM) on each ONH radial scan to calculate the MRW defined as
the shortest distance from BMO to ILM, and (2) the macular
GCIPL from the macular cube scan. The Spectralis built-in
segmentation algorithm was used to segment the cpRNFL from
the circular scan. Details of the SALSA have been described
previously.23–25 Briefly, we assumed that each B-scan consists
of several interretinal layers (e.g., the Bruch’s membrane [BM]
layer, the retinal nerve fiber layer [RNFL]). Because the
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interretinal layers have different thicknesses, each layer can be
defined by a curve modeling its skeleton and a filter or set of
filters modeling its thickness. To segment the different layers, it
is sufficient to estimate their skeletons and the hyperpara-
meters of the filters. In this study, we are interested only in the
segmentation of the BM, ILM layers in the ONH scans, and
RNFL and IPL layers in the macular scans. In order to build
connected skeletons, we considered an object-oriented ap-
proach rather than the voxel-oriented approach.26 Therefore,
short segments (20 voxels in our case) are added to or deleted
from the current configuration depending on their state
(connected or not). Note that shorter segments have been
considered in the termination of the skeletons for better
estimation accuracy. The estimation of the model parameters
and hyperparameters are addressed using a Monte Carlo
Markov chain.27 For the BMO identification, once we estimated
the BM layer separately in each of the 48 B-scans, we utilized
the whole 3D volume to estimate the BMO points to take into
account the planarity of the BMO points. Our aim is to
properly integrate the elliptical shape of the BMO curve and to
rely only on the reliable BMO points in the estimation scheme.
Note that our aim is not to fit an ellipse to the data but to use
the elliptical shape as a Bayesian ‘‘prior’’ shape to estimate the
curve that best represents the data. An elegant way to address
this task is to use the inverse artificial neural network ANN-PCA
to model the elliptical shape of the BMO curve.28
Bayesian-Kernel Detection Scheme
The Bayesian-kernel detection scheme is a Bayesian-based
approach that uses change in the 3D ONH volume scans to
classify an eye as ‘‘nonprogressing’’ or ‘‘progressing.’’ Details of
the BKDS have been described previously.18,19 In brief, raw 3D
SD-OCT ONH cube scans were exported to a numerical
computing language (MATLAB, MathWorks). The Bayesian-
kernel detection scheme was used to estimate glaucoma
progression from ONH cube scans. We formulated the
detection of glaucomatous change between baseline image
and follow-up images as a missing data problem. Markov
random field model (MRF) prior was used to model the spatial
dependency of changed voxels. Once the change detection
map was estimated, we used a kernel-based classifier for
glaucoma progression detection. As prior knowledge or an
agreed-upon ‘‘gold standard’’ for detection of progression in
advanced glaucoma is not available, we used a one-class
classifier trained only on the nonprogressing 50 stable
glaucoma eyes and 36 healthy eyes. We utilized a support
vector data description (SVDD) classifier.19 The SVDD enables
us to distinguish between targets (nonprogressing eyes) and
outliers (progressing eyes) by defining a closed boundary
around the target data. As done previously,29 we included two
features as input for the SVDD based on a glaucoma-related
region of interest of the baseline image that generally consists
of the RNFL, neuoretinal rim, and prelamina tissue of the ONH
identified using SALSA. Follow-up images were automatically
registered by the instrument to the baseline image to detect
change over time at specific locations in the region of interest.
Please note that retinal layer segmentation of the follow-up
images is not required. The two features identified in the
region of interest are the number of voxels detected as
‘‘changed,’’ and the ratio image intensity between the baseline
and follow-up scans of changed voxels.
Definition of Progression
An eye was defined as progressing if (1) macular GCIPL, MRW,
or cRNFL loss was significantly (P < 0.05) different from zero
and faster than the 5th percentile of the healthy group or (2)
3D ONH volume BKDS change was classified as progressing
utilizing both the healthy group and stable glaucoma group in
the one-class SVDD classification method.
Statistical Analysis
Descriptive statistics were used to compare demographic
characteristics by group (healthy and glaucoma subjects). v2
tests were used to compare categorical variables, and t-tests
were used to compare continuous variables. Mixed effects
models were used to calculate the mean rates of change
(slopes) for global cpRNFL thickness, global MRW thickness,
and global macular GCIPL thickness loss from baseline. Models
included group (healthy versus glaucoma), time, and the
interaction term group 3 time. P values less than 0.05 were
considered statistically significant. The model was adjusted for
age, and the correlation between eyes was accounted for in the
model. Statistical analysis was performed using SAS, Version 9.2
(SAS Institute, Cary, NC, USA).
RESULTS
The study included 35 eyes of 35 glaucoma patients with very
advanced glaucoma, 50 eyes from 27 stable glaucoma, and 46
eyes from 30 healthy subjects. A summary of the demographic
variables and measurements at baseline of each group is shown
TABLE 1. Baseline Characteristics of Study Subjects
Healthy Stable Advanced Glaucoma ANOVA P Value
Number of eyes 46 50 35
Sex, % female 55 61 57 0.74
Age at baseline, y 59 6 8.7 68 6 7.1 67 6 11.3 <0.001
Follow-up length, y 2.8 6 0.4 5 wk 3.5 6 0.9 <0.001
Axial length, mm 23.9 6 1.6 24.2 6 2.1 24.3 6 2.4 0.65
Heidelberg Retina Tomograph optic disc area, mm2 2.17 6 0.44 2.19 6 0.41 2.16 6 0.47 0.57
Mean deviation, dB (range) 1.02 (1.2 to 2.3) 6.3 (11.4 to 1.3) 28 (33 to 21) <0.001
All values are mean (6SD) and ANOVA results with post hoc Tukey test P values reported representing the differences between healthy and
glaucoma eyes.
TABLE 2. Baseline Global cpRNFL, MRW, and Macular GCIPL
Measurements by Group
Healthy
Advanced
Glaucoma P Value
cpRNFL, lm 94.3 6 10.4 56.2 6 5.11 <0.001
MRW, lm 211.5 6 59.3 134.6 6 18.7 <0.001
Macular GCIPL, lm 89.7 6 7.5 61.4 6 9.1 <0.001
All values are mean (6SD) and Wilcoxon rank sum test P values
reported representing the differences between healthy and advanced-
glaucoma eyes.
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in Table 1. Glaucoma patients were significantly older (P <
0.001) and had worse VF MD (P < 0.001) and longer follow-up
(P < 0.001) than healthy subjects. The advanced-glaucoma and
the healthy eye groups were similar with respect to sex (P ¼
0.74), axial length (P ¼ 0.65), and disc area (P ¼ 0.57).
Structural Rate of Change
Baseline global cpRNFL thickness derived from the circular
scan, global MRW thickness derived from the ONH radial scan,
and macular GCIPL thickness derived from the entire macular
cube SD-OCT scan measurements in healthy and advanced-
glaucoma eyes are presented in Table 2. Healthy eyes had
thicker baseline cpRNFL, MRW, and macular GCIPL when
compared to glaucoma eyes.
Rates of global cpRNFL, MRW, and macular GCIPL thickness
loss in healthy and advanced-glaucoma eyes are presented in
Figure 1 and Table 3. In healthy eyes, mean rates (P value) of
cpRNFL, MRW, and macular GCIPL were 0.32 lm/y (P <
0.001),1.41 lm/y (P < 0.001), and0.11 lm/y (P < 0.001),
respectively. In advanced-glaucoma eyes, the mean rates of
cpRNFL, MRW, and macular GCIPL change were0.08 lm/y (P
¼ 0.39), 0.29 lm/y (P ¼ 0.43), and 0.18 lm/y (P < 0.02),
respectively. There was no statistically significant difference
between the mean rate of loss of cpRNFL and MRW in
advanced-glaucoma eyes and healthy eyes (P ¼ 0.44 and P ¼
0.58). The mean rate of macular GCIPL loss tended to be larger
in advanced-glaucoma eyes than in healthy eyes, but the
difference in mean rates between the two groups was not
statistically significant (P ¼ 0.12).
Glaucoma Progression Detection
By the structural measurement rate of change criterion, the
number of identified progressing glaucoma eyes was 2 (5%)
using cpRNFL, 4 (11%) using the MRW, and 11 (31%) using the
macular GCIPL. Table 4 presents baseline global cpRNFL, MRW,
macular GCIPL, and VF MD measurements by study group;
Table 5 presents the mean rates of global cpRNFL, MRW,
macular GCIPL, and VF MD loss by study group. No significant
TABLE 3. Rates of Global cpRNFL, MRW, Macular GCIPL, and VF MD Loss by Group
Healthy, n ¼ 46 Advanced Glaucoma, n ¼ 35
P Value*Mean (95% CI) P Value Mean (95% CI) P Value
cpRNFL, lm/y 0.32 (0.51, 0.14) <0.001 0.08 (0.21, 0.19) 0.39 0.44
MRW, lm/y 1.41 (1.45, 1.18) <0.001 0.29 (0.86, 0.73) 0.43 0.58
GCIPL, lm/y 0.11 (0.15, 0.01) <0.001 0.18 (0.25, 0.06) 0.02 1.12
VF MD, dB/y 0.07 (0.19, 0.26) 0.65 0.02 (0.08, 0.16) 0.47 0.82
CI, confidence interval.
* P value evaluates differences in the mean rate of change between healthy and glaucoma eyes.
TABLE 4. Baseline Global cpRNFL, MRW, Macular GCIPL, and VF MD Measurements by Group
3D Whole-Volume BKDS Criterion Macular GCIPL Criterion
Nonprogressing, n ¼ 22 Progressing, n ¼ 13
P Value
Nonprogressing, n ¼ 24 Progressing, n ¼ 11
P ValueMean 6 SD Mean 6 SD Mean 6 SD Mean 6 SD
cpRNFL, lm 55.7 6 5.3 56.7 6 6.4 0.72 54.2 6 6.4 58.2 6 7.1 0.39
MRW, lm 133.8 6 19.5 135.4 6 21.3 0.84 132.4 6 21.3 136.8 6 22.4 0.43
GCIPL, lm 59.1 6 8.7 63.7 6 9.5 0.15 59.8 6 8.2 63 6 9.8 0.09
VF MD, dB 26.4 6 2.9 29.6 6 3.8 0.11 27.7 6 3.1 28.3 6 3.4 0.34
All values are mean (6SD) and Wilcoxon rank sum test of the differences between nonprogressing and progressing glaucoma eyes.
TABLE 5. Rate of Global cpRNFL, MRW, Macular GCIPL, and VF MD Loss by Group
3D Whole-Volume BKDS Criterion Macular GCIPL Criterion
Nonprogressing, n ¼ 22 Progressing, n ¼ 13
P Value
Nonprogressing, n ¼ 24 Progressing, n ¼ 11
P ValueMean 6 SD Mean 6 SD Mean 6 SD Mean 6 SD
cpRNFL, lm/y 0.07 6 0.02 0.09 6 0.03 0.48 0.06 6 0.01 0.08 6 0.03 0.37
MRW, lm/y 0.27 6 0.07 0.33 6 0.11 0.71 0.28 6 0.06 0.32 6 0.12 0.58
GCIPL, lm/y 0.11 6 0.04 0.24 6 0.05 0.03 0.1 6 0.05 0.27 6 0.05 0.01
VF MD, dB/y 0.02 6 0.01 0.04 6 0.02 0.34 0.05 6 0.02 0.04 6 0.03 0.20
All values are mean (6SD) and Wilcoxon rank sum test of the differences between nonprogressing and progressing glaucoma eyes.
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difference was found between the VF MD baseline measure-
ment and MD mean rate of change of the 11 eyes that
progressed based on the macular GCIPL criteria and 24 eyes
that did not progress (P ¼ 0.34, P ¼ 0.2, respectively).
However, mean macular GCIPL thickness tended to be larger in
the 11 eyes that progressed compared to the eyes that did not
(P¼ 0.09). There was no significant difference in cpRNFL and
MRW thickness and mean rate of change between the 11
progressing eyes based on GCIPL and the eyes that did not
progress (P ¼ 0.39, P ¼ 0.43 and P ¼ 0.37, P ¼ 0.58,
respectively). Figure 2 shows the cpRNFL, MRW, macular
GCIPL thickness, and VF of an eye identified as progressing by
cpRNFL, MRW, and macular GCIPL. Figure 3 shows the
cpRNFL, MRW, macular GCIPL thickness, and VF of an eye
with progression detected only by macular GCIPL.
Using the 3D whole-volume BKDS method, the number of
progressing glaucoma eyes identified was 13 (31%). Among the
13 progressing eyes detected by the 3D whole-volume BKDS, 7
eyes were also identified by macular GCIPL, 3 eyes by MRW,
and 1 eye by cpRNFL. Using the 3D whole-volume BKDS
method, no significant difference was found between the VF
MD baseline measurement and MD rate of change of the 13
eyes that progressed based on the BKDS and 22 eyes that did
not progress (P¼ 0.11, P¼ 0.3, respectively). The GCIPL mean
rate of change was significantly faster in BKDS progressing eyes
than nonprogressing eyes (P¼ 0.03). There was no significant
difference in baseline cpRNFL and MRW thickness and mean
rate of change between the 13 BKDS progressing eyes and 22
nonprogressing eyes (P¼ 0.72, P¼ 0.84 and P¼ 0.48 and P¼
71, respectively).
DISCUSSION
Our results suggest that even in very advanced glaucoma,
structural loss can be detected in some eyes using standard
global structural measures. Specifically, macular GCIPL had the
highest proportion of eyes with detectable change (31%),
followed by MRW (11%) and cpRNFL (4%). In addition, the 3D
whole-volume BKDS change method, which does not require
extensive retinal layer segmentation, detected change in 37%
of eyes. Moreover, only the mean rate of macular GCIPL change
reached statistical significance, suggesting that GCIPL changes
can be detected even in this group of severely advanced-OAG
eyes. In contrast, the mean rates of change in cpRNFL and
MRW were not significantly different from zero. The mean
rates of change in the healthy eyes were all significantly
different from zero, suggesting that aging effects can be
detected even in a relatively short follow-up time.
These results are important as detecting change in
advanced-OAG eyes is challenging, as the amount of remaining
measurable neural tissue is limited. Moreover, determining
whether the glaucoma patient is stable or progressing is critical
for determining whether the treatment initiated needs to be
changed or intensified, as patients with advanced glaucoma are
at a high risk of losing remaining vision and becoming
functionally impaired or blind from the disease.
This study is unique in that it focused on identification of
change in very advanced disease where the usefulness of
conventional structural and functional tests that usually guide
treatment decisions is reduced (i.e., VF and cpRNFL thickness).
While the VF MD is commonly used to classify the glaucoma
subject into early, moderate, and advanced disease, it may not
accurately reflect the extent of structural loss. For example,
one eye with only a focal cpRNFL defect may have the same VF
MD value as another eye with a diffuse cpRNFL defect. In the
first case it is possible that the RNFL thickness in sectors
without the focal defect can still be used to monitor further
change, which is less likely the case for the second eye.
Therefore, this report can be considered as a proof of concept;
if structural change was detectable in this very advanced stage
of the disease using existing and novel methods for change
detection, then structural change is also likely to be detectable
in eyes with less advanced disease.
FIGURE 1. Distribution of the mean rates of change of circumpapillary
retinal nerve fiber layer (cpRNFL), minimum rim width (MRW), and
macular ganglion cell–inner plexiform layer (GCIPL) thickness in
healthy and advanced-glaucoma eyes.
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Recent advances in SD-OCT technology have improved
image resolution, made it possible to measure retina layer
thickness and ONH parameters, and allowed the imaging of
deeper retinal structures such as the choroid and the lamina
cribrosa.30 For these reasons, SD-OCT has been widely adopted
clinically to objectively assess small changes in the retina. In
the current study, we evaluated the rate of change of cpRNFL
thickness, MRW, and macular GCIPL in advanced-glaucoma
eyes and compared the number of progressing glaucoma eyes
using these measurements to a new 3D optic ONH whole-
volume change detection method, BKDS, that does not require
retinal layer segmentation.
Retinal layer segmentation is particularly challenging in eyes
with advanced disease as the layers are thin, and results are
more variable than in eyes with less severe glaucoma. This
issue is of particular importance for cpRNFL segmentation, as
the presence of large blood vessels can adversely affect
segmentation of the thin cpRNFL in advanced disease.31
Similarly, differentiating between the ganglion cell layer
(GCL) and IPL is particularly challenging when the layers are
thin, as in advanced OAG. For this reason, we analyzed the
macular GCIPL and not the GCL as a separate layer. The SALSA
and Spectralis instrument–based retinal layer segmentation of
eyes included in this study were manually checked and did not
have segmentation failures of the macular GCIPL, MRW, or
cpRNFL.
There are several possible reasons why we found faster
cpRNFL and MRW change in healthy subjects than in advanced-
glaucoma patients. First, healthy subjects were younger than
OAG patients and had thicker baseline values. In addition,
cpRNFL and MRW atrophy is already extensive in patients with
advanced glaucoma. Therefore, identification of cpRNFL and
MRW changes is more challenging at later stages of glaucoma
when the layers have already thinned.
The 3D whole-volume BKDS offers several advantages
compared to retinal structural- and thickness-based methods.
First, the 3D whole-volume BKDS does not require accurate
segmentation of each retinal layer on each scan. Rather, a
glaucoma-based region of interest, generally consisting of
RNFL, neuroretinal rim, and prelamina tissue, is delineated
on the baseline scan only. Therefore, measurement variability
inherent in retinal layer segmentation algorithms will not
adversely affect the ability to detect progression. The BKDS
also facilitates the analysis of the entire ONH 3D volume for
potential glaucomatous changes that may occur in the region
of interest that also includes deeper layers such as prelaminar
tissue. Moreover, the use of spatial dependency favors the
generation of homogeneous areas, reducing the likelihood of
false-positive detection of change. Third, the proposed kernel-
based support vector data description (SVDD) method allows
the classifier to be trained using only nonprogressing eyes. This
is important because there is no generally accepted definition
or ‘‘gold standard’’ for detection of progression in advanced
glaucoma that can be used to identify progressing eyes for use
in training the classifier. It is important to note that we have
previously demonstrated the utility of the BKDS for detection
of ONH progression in early- to moderate-glaucoma eyes using
VF progression as the ‘‘gold standard.’’18,19 Finally, BKDS can
FIGURE 2. Top row: circumpapillary retinal nerve fiber layer (cpRNFL), minimum rim width (MRW), Bottom row: macular ganglion cell–inner
plexiform layer (GCIPL) thickness, and 24-2 visual field in one eye detected as glaucoma progressing by cpRNFL, MRW, and macular GCIPL (MD VF¼
22.3).
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be tailored to specific progression detection tasks. For
example, in our previous publications, BKDS was implemented
without any retinal layer segmentation.18 In the current study,
a region of interest was defined by segmentation of the
baseline images and progression detection limited to the
designated region of interest.
There are several limitations to the 3D whole-volume
BKDS method that should be noted. One limitation of the
proposed method is the inclusion of retinal blood vessels in
the change detection map. Although the variation of retinal
blood vessels may be compensated for by the classifier, this
compensation by the classification algorithm could mask
small changes in the RNFL or rim area. Another limitation is
the lack of a parameter to assess and quantify the rate of
progression, which may be helpful for clinicians to estimate
the likelihood that a patient will become functionally
impaired in his or her lifetime.16 Further, it is difficult to
assess whether the detected changes are due to glaucomatous
changes or other tissue remodeling that is not related to
progression of the disease. Nevertheless, while it is unclear if
the detected changes are related or not to the glaucoma, it is
important for the clinician to evaluate change that is outside
normal limits.
Limitations of the current study include the small sample
size, relative short follow-up time for both healthy subjects
and glaucoma patients, and the limited age range of the
healthy subjects. For these reasons, the proportion of
progressing eyes and rates of change measured for GCIPL,
MRW, and cpRNFL in this specific severely advanced-
glaucoma group may not be generalizable to other groups
of advanced-glaucoma patients. In addition, without a gold
standard definition of progression in advanced disease, it is
difficult to determine whether the detected changes are
glaucomatous changes or age-related changes, or, as previ-
ously mentioned, to tissue remodeling not necessarily related
to OAG. We utilized nonprogressing healthy and stable
glaucoma eyes in the analysis to reduce the possibility that
the changes identified were due to aging or variability of the
measurements. Nevertheless, while it is unclear if the
detected changes are related or not to the glaucoma,
characterizing these changes may improve our understanding
of the pathophysiology of glaucoma or age-related changes in
these eyes with advanced disease. Another limitation is the
use of the global measurements to assess the rate of change of
cpRNFL, MRW, and GCIPL. While using global measurements
results in reduced variability compared to sectoral measure-
ments, in advanced OAG, they may underestimate the
changes at locations where there is a region in which neural
tissue remains intact. The development of automated
methods to detect the remaining neural tissue may be helpful
to assess more accurately regions of interest for monitoring
the structural rate of change.
In conclusion, our results suggest that even in very
advanced disease, structural change can be detected, and that
monitoring macular GCIPL and 3D whole-volume BKDS
change shows promise for identifying progression in advanced
glaucoma. However, a larger sample of advanced-glaucoma
patients with longer follow-up is needed to validate these
findings.
FIGURE 3. Top row: circumpapillary retinal nerve fiber layer (cpRNFL), minimum rim width (MRW), Bottom row: macular ganglion cell–inner
plexiform layer (GCIPL) thickness, and 24-2 visual field in one eye detected as glaucoma progressing by only macular GCIPL (MD VF ¼28.46).
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